We joined with the Arthritis Foundation on a letter signed by 20 patient groups to HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Oz regarding TrumpRx, thanking them for their efforts for lowering Rx costs, but highlighting the need to ensure that patients are aware that their costs do not count towards their insurance requirements and cost-sharing.
Comments to Oregon PDAB on PBM reform, transparency, and increasing prescription drug access
As a national patient advocacy organization that works to promote quality and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic conditions, we see firsthand how PBM practices, pharmacy access, and insurance design determine whether patients can remain on lifesaving treatment. We appreciate the Board’s continued focus on practical, patient-centered reforms that Oregon can move forward with.
Support for Wisconsin copay accumulator ban
By passing Senate Bill 203, Wisconsin will join 25 other states, the District of Columbia, and Puerto Rico in protecting consumers purchasing insurance on the private market. This legislation ensures that copay assistance counts toward cost-sharing obligations, preventing patients from facing insurmountable financial barriers to their medications.
Amicus brief in support of Iowa’s copay assistance law
HIV+Hep filed an amicus brief in support of Iowa’s PBM reform law that requires copay assistance to count for Rx’s not only in ACA plans but for the first time, employer plans. PBMs contend it is unlawful under ERISA. In our brief we explain to the US 8th Circuit Court of Appeals why it is not.
HIV Groups letter to CVS Health on not covering Yeztugo
We, the undersigned 64 organizations, on behalf of people and communities affected by HIV, their care providers, public health practitioners, and community-based organizations, write in response to statements made by CVS Health to the media that it does not intend to cover Yeztugo (lenacapavir), a twice-yearly long-acting injectable drug recently approved by the FDA as pre-exposure prophylaxis (PrEP) for the prevention of HIV.[1] We urge you to reconsider this decision and cover Yeztugo without delay.